D-Allo-Thr(5)-Liraglutide

Name: D-Allo-Thr(5)-Liraglutide
Brand: SIAL

GLP-1 Agonist Impurity, analytical standard, Numbering in the name as per API

Synonym(e):

D-allo-Thr(11)-Liraglutide, H-His-Ala-Glu-Gly-D-allo-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Glu-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Kyn-Leu-Val-Arg-Gly-Arg-Gly-OH

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Über diesen Artikel

Empirische Formel (Hill-System):

C₁₇₂H₂₆₅N₄₃O₅₁

Molekulargewicht:

3751.20

UNSPSC Code:

41116107

eCl@ss:

25140904

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Eigenschaften

grade

analytical standard

Quality Segment

100

API family

liraglutide, liraglutide, liraglutide, liraglutide

form

solid

technique(s)

HPLC: suitable, LC/MS: suitable, liquid chromatography (LC): suitable, mass spectrometry (MS): suitable

format

neat

SMILES string

OC[C@@H](C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC)=O)=O)C(N[C@H](C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)=O)=O)=O)C)=O)=O)CC4=CC=CC=C4)=O)CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC5=CC=CC=C5)NC([C@H]([C@@H](O)C)NC(CNC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](CC6=CNC=N6)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Beschreibung

General description

This analytical standard of D-Allo-Thr(5)-Liraglutide, API numbering D-Allo-Thr(11)-Liraglutide is a diastereomeric impurity of Liraglutide resulting from the incorporation of D-allo-Threonine—the diastereomer of L-Threonine with inverted configuration at both the α- and β-carbons—at position 5 (API numbering). This substitution can originate from racemisation or epimerisation of the Thr building block during SPPS. The compound otherwise retains the complete Liraglutide structure, including the palmitoyl–γGlu–Lys26 fatty acid modification. The D-allo configuration at Thr5 is expected to perturb local backbone geometry and helix formation, with potential consequences for receptor engagement.

Application

Used as an analytical standard for the identification and semi-quantification of the D-allo-Thr-5 diastereomeric impurity in Liraglutide API by reversed-phase HPLC, chiral chromatography, and LC-MS/MS methods.